Malcolm Brenner VIEW CLINICAL PROFILE

Malcolm Brenner, MD, PhD

Full Affiliate Member, Research Institute
Houston Methodist


VIEW CLINICAL PROFILE
Biography

Dr. Brenner completed his postdoctoral training in 1981 and joined the Clinical Research Centre of Northwick Park Hospital in London, England as a MRC Clinical Scientist and Honorary Senior Registrar. He also began lecturing in Haematology at the Royal Free Hospital and Hospital for Sick Children, also in London.

Dr. Brenner joined the faculty at the University of Tennessee in Memphis as a Professor in the Departments of Pediatrics and Medicine in 1990. He also became the Director of the Bone Marrow Transplant Division of the St. Jude Children's Research Hospital that same year. He later directed the Cell and Gene Therapy Program at St. Jude's from 1994 until 1997, when he assumed his current positions at the Baylor College of Medicine.

Description of Research

Dr. Brenner's research focuses on gene transfer to stem cells and to effector cells of the immune system. His research group was one of the first to use gene transfer in human subjects, establishing the feasibility of tracking human stem cells and their progeny in subjects with cancer. Dr. Brenner also develops tumor vaccines for pediatric and hematological malignancies, using genetic modification with retroviral and adenoviral vectors.

Areas Of Expertise

Stem cells Gene therapy Cell therapy Vectors
Education & Training

PhD, University of Cambridge
Publications

LOAd703, an oncolytic virus-based immunostimulatory gene therapy, combined with chemotherapy for unresectable or metastatic pancreatic cancer (LOKON001): results from arm 1 of a non-randomised, single-centre, phase 1/2 study
Musher, BL, Rowinsky, EK, Smaglo, BG, Abidi, W, Othman, M, Patel, K, Jawaid, S, Jing, J, Brisco, A, Leen, AM, Wu, M, Sandin, LC, Wenthe, J, Eriksson, E, Ullenhag, GJ, Grilley, B, Leja-Jarblad, J, Hilsenbeck, SG, Brenner, MK & Loskog, ASI 2024, , The Lancet Oncology, vol. 25, no. 4, pp. 488-500. https://doi.org/10.1016/S1470-2045(24)00079-2

Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial
Hegde, M, Navai, S, DeRenzo, C, Joseph, SK, Sanber, K, Wu, M, Gad, AZ, Janeway, KA, Campbell, M, Mullikin, D, Nawas, Z, Robertson, C, Mathew, PR, Zhang, H, Mehta, B, Bhat, RR, Major, A, Shree, A, Gerken, C, Kalra, M, Chakraborty, R, Thakkar, SG, Dakhova, O, Salsman, VS, Grilley, B, Lapteva, N, Gee, A, Dotti, G, Bao, R, Salem, AH, Wang, T, Brenner, MK, Heslop, HE, Wels, WS, Hicks, MJ, Gottschalk, S & Ahmed, N 2024, , Nature Cancer. https://doi.org/10.1038/s43018-024-00749-6

Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas
Hill, LQC, Rouce, RH, Wu, MJ, Wang, T, Ma, R, Zhang, H, Mehta, B, Lapteva, N, Mei, Z, Smith, TS, Yang, L, Srinivasan, M, Burkhardt, PM, Ramos, CA, Lulla, P, Arredondo, M, Grilley, B, Heslop, HE, Brenner, MK & Mamonkin, M 2024, , Blood, vol. 143, no. 13, pp. 1231-1241. https://doi.org/10.1182/blood.2023022204

Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis
Mo, F, Tsai, CT, Zheng, R, Cheng, C, Heslop, HE, Brenner, MK, Mamonkin, M & Watanabe, N 2024, , Cytotherapy. https://doi.org/10.1016/j.jcyt.2024.03.006

Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies
Al Hadidi, S, Heslop, HE, Brenner, M & Suzuki, M 2024, , Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.05.039

Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients
Vasileiou, S, Hill, LQ, Kuvalekar, M, Workineh, AG, Watanabe, A, Velazquez, Y, Lulla, S, Mooney, K, Lapteva, N, Grilley, BJ, Heslop, HE, Rooney, CM, Brenner, MK, Eagar, TN, Carrum, G, Grimes, KA, Leen, AM & Lulla, P 2023, , Haematologica, vol. 108, no. 7, pp. 1840-1850. https://doi.org/10.3324/haematol.2022.281946

Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival
Martinez, C, Aguayo-Hiraldo, P, Chaimowitz, N, Forbes, L, Rider, N, Nicholas, S, Seeborg, F, Chinen, J, Chinn, I, Davis, C, Roseblatt, H, Noroski, L, Omer, B, John, T, Yassine, K, Naik, S, Craddock, J, Bhar, S, Allen, C, Ahmed, N, Sasa, G, Steffin, D, Doherty, E, George, A, Salem, B, Friend, B, Hegde, M, Brenner, MK, Heslop, HE, Leen, A, Peña, A, Wu, M, Hanson, IC & Krance, RA 2023, , Blood Advances, vol. 7, no. 9, pp. 1823-1830. https://doi.org/10.1182/BLOODADVANCES.2022009038

Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: Implications for T-cell immunotherapy
Sharma, S, Woods, M, Mehta, NU, Sauer, T, Parikh, KS, Schmuck-Henneresse, M, Zhang, H, Mehta, B, Brenner, MK, Heslop, HE & Rooney, CM 2023, , Journal for immunotherapy of cancer, vol. 11, no. 4, jitc-2022-006267. https://doi.org/10.1136/jitc-2022-006267

Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies
Wang, D, Porter, CE, Lim, B, Shaw, AR, Robertson, CS, Woods, ML, Xu, Y, Biegert, GGW, Morita, D, Wang, T, Grilley, BJ, Heslop, H, Brenner, MK & Suzuki, M 2023, , Science advances, vol. 9, no. 13, eade6790, pp. eade6790. https://doi.org/10.1126/sciadv.ade6790

Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials
Cornetta, K, Yao, J, House, K, Duffy, L, Adusumilli, PS, Beyer, R, Booth, C, Brenner, M, Curran, K, Grilley, B, Heslop, H, Hinrichs, CS, Kaplan, RN, Kiem, HP, Kochenderfer, JN, Kohn, DB, Mailankody, S, Norberg, SM, OCearbhaill, RE, Pappas, J, Park, J, Ramos, C, Ribas, A, Rivière, I, Rosenberg, SA, Sauter, C, Shah, NN, Slovin, SF, Thrasher, A, Williams, DA & Lin, TY 2023, , Molecular Therapy, vol. 31, no. 3, pp. 801-809. https://doi.org/10.1016/j.ymthe.2022.12.006

Novel banana lectin CAR-T cells to target pancreatic tumors and tumor-associated stroma
McKenna, MK, Ozcan, A, Brenner, D, Watanabe, N, Legendre, M, Thomas, DG, Ashwood, C, Cummings, RD, Bonifant, C, Markovitz, DM & Brenner, MK 2023, , Journal for immunotherapy of cancer, vol. 11, no. 1, A10. https://doi.org/10.1136/jitc-2022-005891

Engineering T cells to suppress acute GVHD and leukemia relapse after allogeneic hematopoietic stem cell transplantation
Mo, F, Watanabe, N, Omdahl, KI, Burkhardt, PM, Ding, X, Hayase, E, Panoskaltsis-Mortari, A, Jenq, RR, Heslop, HE, Kean, LS, Brenner, M, Tkachev, V & Mamonkin, M 2023, , Blood, vol. 141, no. 10, pp. 1194-1208. https://doi.org/10.1182/blood.2022016052

Emerging Challenges to Cellular Therapy of Cancer
Lulla, PD & Brenner, M 2023, , Cancer Journal (United States), vol. 29, no. 1, pp. 20-27. https://doi.org/10.1097/PPO.0000000000000637

Targeting glycans for CAR therapy: The advent of sweet CARs
Raglow, Z, McKenna, MK, Bonifant, CL, Wang, W, Pasca di Magliano, M, Stadlmann, J, Penninger, JM, Cummings, RD, Brenner, MK & Markovitz, DM 2022, , Molecular Therapy, vol. 30, no. 9, pp. 2881-2890. https://doi.org/10.1016/j.ymthe.2022.07.006

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs
Steffin, DHM, Muhsen, IN, Hill, LQC, Ramos, CA, Ahmed, N, Hegde, M, Wang, T, Wu, M, Gottschalk, S, Whittle, SB, Lulla, PD, Mamonkin, M, Omer, B, Rouce, RH, Heczey, A, Metelitsa, LS, Grilley, BJ, Robertson, C, Torrano, V, Lapteva, N, Gee, AP, Rooney, CM, Brenner, MK & Heslop, HE 2022, , Blood, vol. 140, no. 1, pp. 16-24. https://doi.org/10.1182/blood.2022015728

Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL
Naik, S, Vasileiou, S, Tzannou, I, Kuvalekar, M, Watanabe, A, Robertson, C, Lapteva, N, Tao, W, Wu, M, Grilley, B, Carrum, G, Kamble, RT, Hill, LQ, Krance, RA, Martinez, C, Tewari, P, Omer, B, Gottschalk, S, Heslop, HE, Brenner, MK, Rooney, CM, Vera, JF, Leen, AM & Lulla, PD 2022, , Blood, vol. 139, no. 17, pp. 2706-2711. https://doi.org/10.1182/blood.2021014648

Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy
Atilla, PA, McKenna, MK, Watanabe, N, Mamonkin, M, Brenner, MK & Atilla, E 2022, , Cytotherapy, vol. 24, no. 3, pp. 282-290. https://doi.org/10.1016/j.jcyt.2021.10.007

Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies
Watanabe, N, Mo, F, Zheng, R, Ma, R, Bray, VC, van Leeuwen, DG, Sritabal-Ramirez, J, Hu, H, Wang, S, Mehta, B, Srinivasan, M, Scherer, LD, Zhang, H, Thakkar, SG, Hill, LQC, Heslop, HE, Cheng, C, Brenner, MK & Mamonkin, M 2023, , Molecular Therapy, vol. 31, no. 1, pp. 24-34. https://doi.org/10.1016/j.ymthe.2022.09.003

Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors
Rosewell Shaw, A, Porter, CE, Yip, T, Mah, WC, McKenna, MK, Dysthe, M, Jung, Y, Parihar, R, Brenner, MK & Suzuki, M 2021, , Communications Biology, vol. 4, no. 1, 368. https://doi.org/10.1038/s42003-021-01914-8

Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity: Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity (Molecular Therapy (2021) 29(5) (1808–1820), (S152500162100071X), (10.1016/j.ymthe.2021.02.004))
McKenna, MK, Englisch, A, Brenner, B, Smith, T, Hoyos, V, Suzuki, M & Brenner, MK 2021, , Molecular Therapy, vol. 29, no. 12, pp. 3529-3533. https://doi.org/10.1016/j.ymthe.2021.10.007

VIEW FULL PUBLICATIONS